ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Electra Therapeutics, Inc.
$8.61−0.14 (-1.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Electra Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Electra Therapeutics, Inc. is listed on Nasdaq under the ticker ETRA, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Electra Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 230 East Grand Avenue, Suite S-100 94080
- Phone
- (888) 743-2290
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ETRA
- Exchange
- Nasdaq
- IPO date
- Sep 18, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2088082
- CUSIP
- 269246401
- ISIN
- US2692464017
- EIN
- 83-2193635
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Quehuong (Kathy) Dong | President & CEO, Director | 455,484 |
| Gary S. Koe | Chief Technical Officer | 63,656 |
| Graham Parry | Chief Scientific Officer | 85,504 |
| David J. Tucker | Principal Accounting Officer | – |
| Christopher William Clark | Chief Financial Officer | – |
| Kim-Hien Dao | Chief Medical Officer | – |
| Carl L. Gordon | Director | 758,279 |
| Genesis GP LLC OrbiMed | Director | – |
| Capital GP VII LLC OrbiMed | Director | 5,126,891 |
| Advisors Llc Orbimed | Director | – |
| Nancy Stagliano | Director | 255,635 |
| Matthew K. Fust | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 18, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |